# Rheumatology Domain - Domain-Driven Design

## Overview

This domain applies Domain-Driven Design (DDD) principles to rheumatology systems. Rheumatology encompasses the diagnosis and management of autoimmune and inflammatory diseases affecting joints, muscles, and connective tissues. The domain model captures clinical assessment workflows, disease management strategies, biologic therapy administration, pain management protocols, and longitudinal outcomes tracking.

DDD provides a natural fit for rheumatology because the field involves complex clinical decision-making, interdisciplinary collaboration, and the need for precise terminology shared across rheumatologists, nurses, pharmacists, physical therapists, and system developers.

## Bounded Contexts

The rheumatology domain is decomposed into six bounded contexts that reflect the natural divisions in clinical practice.

### Clinical Assessment Context

Manages joint examinations, serologic testing, and disease activity scoring. This context captures the initial and ongoing evaluation of patients, including tender joint counts, swollen joint counts, rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP) antibodies, antinuclear antibody (ANA) panels, and composite disease activity indices such as DAS28, CDAI, and SDAI.

### Autoimmune Disease Context

Handles the classification and management of systemic autoimmune diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), scleroderma, vasculitis, and Sjogren's disease. This context applies ACR/EULAR classification criteria, tracks disease activity using validated indices (DAS28, SLEDAI), and manages treatment escalation strategies.

### Joint Disease Context

Covers non-autoimmune joint diseases including osteoarthritis, gout, crystal arthropathy, and joint injection therapy. This context manages synovial fluid analysis, urate-lowering therapy for gout, and procedural documentation for intra-articular injections.

### Biologic Therapy Context

Governs the prescribing, administration, and monitoring of biologic and targeted synthetic DMARDs. This includes TNF inhibitors (adalimumab, etanercept, infliximab), IL-6 receptor blockers (tocilizumab, sarilumab), JAK inhibitors (tofacitinib, baricitinib, upadacitinib), biosimilar switching protocols, infusion management, and safety monitoring (tuberculosis screening, hepatitis panels, infection surveillance).

### Pain Management Context

Addresses multimodal pain assessment and intervention strategies. This context coordinates pharmacologic pain management (NSAIDs, corticosteroids, analgesics), physical therapy referrals and progress tracking, occupational therapy for joint protection and adaptive devices, and patient education on self-management strategies.

### Outcomes Tracking Context

Tracks longitudinal patient outcomes using validated instruments. This context captures DAS28 scores over time for treat-to-target monitoring, HAQ-DI functional disability assessments, radiographic progression scoring (Sharp/van der Heijde method), and patient-reported outcome measures (PROMIS, EQ-5D).

## Topics

- [Strategic Design](topics/strategic-design/)
- [Bounded Contexts](topics/bounded-contexts/)
- [Context Map](topics/context-map/)
- [Ubiquitous Language](topics/ubiquitous-language/)
- [Subdomains](topics/subdomains/)
- [Anti-Corruption Layer](topics/anti-corruption-layer/)
- [Aggregates](topics/aggregates/)
- [Entities](topics/entities/)
- [Value Objects](topics/value-objects/)
- [Domain Events](topics/domain-events/)
- [Repositories](topics/repositories/)
- [Domain Services](topics/domain-services/)
- [Clinical Assessment Context](topics/clinical-assessment-context/)
- [Autoimmune Disease Context](topics/autoimmune-disease-context/)
- [Joint Disease Context](topics/joint-disease-context/)
- [Biologic Therapy Context](topics/biologic-therapy-context/)
- [Pain Management Context](topics/pain-management-context/)
- [Outcomes Tracking Context](topics/outcomes-tracking-context/)
- [Event-Driven Architecture](topics/event-driven-architecture/)
- [Integration Patterns](topics/integration-patterns/)
- [Rheumatology Standards](topics/rheumatology-standards/)
- [Regulatory Compliance](topics/regulatory-compliance/)

## References

- Evans, Eric. Domain-Driven Design: Tackling Complexity in the Heart of Software. Addison-Wesley, 2003.
- Vernon, Vaughn. Implementing Domain-Driven Design. Addison-Wesley, 2013.
- Khononov, Vlad. Learning Domain-Driven Design. O'Reilly Media, 2021.
- Aletaha, D., et al. "2010 Rheumatoid Arthritis Classification Criteria: An ACR/EULAR Collaborative Initiative." Arthritis & Rheumatism, vol. 62, no. 9, 2010, pp. 2569-2581.
- Smolen, J.S., et al. "EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological DMARDs: 2022 Update." Annals of the Rheumatic Diseases, 2023.
- Fanouriakis, A., et al. "EULAR Recommendations for the Management of Systemic Lupus Erythematosus: 2023 Update." Annals of the Rheumatic Diseases, 2024.
- Singh, J.A., et al. "2015 ACR Guideline for the Treatment of Rheumatoid Arthritis." Arthritis & Rheumatology, vol. 68, no. 1, 2016, pp. 1-26.
- FitzGerald, J.D., et al. "2020 ACR Guideline for Management of Gout." Arthritis Care & Research, vol. 72, no. 6, 2020, pp. 744-760.
